Biotech Earnings Ahead for Exelixis, Gilead Sciences, Incyte
Las Vegas, NV / CRWE PRESS RELEASE / February 8, 2026 - Among the companies expected to release their financial results on Tuesday, February 10, are:
Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company focused on oncology therapies, will release its fourth-quarter and full-year 2025 financial results after the market closes. Analysts are forecasting earnings per share (EPS) of $0.81 on revenue of $601.1 million. $EXEL ended Friday’s session at $43.90, up $1.53, or 3.61%.
Gilead Sciences, Inc. (Nasdaq: GILD), a global biopharmaceutical company known for its antiviral and oncology treatments, is scheduled to report its fourth-quarter and full-year 2025 financial results and provide guidance after the closing bell. The consensus estimate calls for EPS of $1.83 on revenue of $7.68 billion. On Friday, $GILD closed at $152.50, gaining $3.13, or 2.10%.
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company specializing in small-molecule therapies, will deliver its fourth-quarter and year-end 2025 financial update before the market opens. Wall Street expects EPS of $1.95 on revenue of $1.35 billion. $INCY finished Friday’s trading session at $108.39, rising $5.63, or 5.48%.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
© 2026 CRWE PRESS RELEASE. All Rights Reserved.
